Become a sponsor and benefit from the advantage to provide a unique opportunity to present your products and to promote your services to the right professionals.
We would be happy to inform you all the details about WASOG 2026 Sponsorship Opportunities. We are open to discuss other sponsorship types that better suits your company marketing strategy. We really want your company to be with us in Porto, we believe we can offer your company great opportunities.
For more information about sponsorship, please contact the Secretariat Skyros Congressos.
Email: sponsors@skyros-congressos.com
Telephone: +351 919 589 180
Xentria is a clinical-stage biopharmaceutical company dedicated to developing therapies for patients with rare and underserved diseases. Our mission is to advance science-driven therapeutics that address conditions where treatment options remain limited and patient burden is high.
A core focus of Xentria’s pipeline is the complex, multi-system inflammatory condition known as sarcoidosis.
XTMAB-16, Xentria’s lead investigational monoclonal antibody, is currently being evaluated in a clinical trial (XTMAB16-201) in patients with pulmonary sarcoidosis. XTMAB-16 is designed to target tumor necrosis factor alpha (TNF-α), a cytokine implicated in granuloma formation and persistent inflammation in sarcoidosis.
Through disciplined clinical development, close collaboration with sarcoidosis experts, and engagement with the sarcoidosis community, Xentria is committed to advancing therapeutic options that may improve outcomes and quality of life for patients living with this challenging rare disease.
20
APR
Abstract Submission Deadline
20
MAY
Author Notification
3
JUN
Early Bird Registration
SecretariatSkyros Congressos
Telephone: +351 919 589 180